미세유체 시장 : 제품별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2030년)

The Microfluidics market is projected to reach USD 37.2 Billion by 2030 from USD 24.96 billion in 2025, growing at a CAGR of 8.3% during the forecast period. The microfluidics market is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of the important factors. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare.

Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery, organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics-associated research.

"Polymers to account for the largest market share in 2024."

The microfluidics market is propelled by polymers because of their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also enable cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers account for the largest share in the microfluidics market.

"Hospital and Diagnostic Centers to register the highest growth rate in the market during the forecast period."

Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The highest CAGR was recorded in the APAC region during the forecast period of 2024- 2029. Asia Pacific includes India, China, Japan, Australia, South Korea, and RoAPAC. Demand for novel technologies is also on the rise, particularly in China, India, and Japan. The government is striving hard to develop research activities in academic setups. In this regard, the Japanese government has distributed USD 64.26 billion toward its 6th Science and Technology Basic Plan for 2021-2025. The rising incidence of chronic and infectious diseases, coupled with increased interest in early diagnosis and preventive care, has enhanced the utilization of microfluidic devices by tremendous bounds. The pharmaceutical and life sciences sectors, which are fast growing in the region, are also driving the research and development efforts, hence increasing the demand for microfluidics.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: C-level-- 10%, Director-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World -8%.

Prominent players in this market are Abbott laboratories (US) , Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD(US), Bio-Rad laboratories, Inc (US), Danaher Corporation (US), Illumina Inc. (US), Parker Hannifin Corporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), Idex Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK) and Elveflow (France).

Research Coverage

The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.

Key Benefits of Buying the Report:

The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.

Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.

Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN MICROFLUIDICS MARKET
• 2.4 HIGH GROWTH SEGMENTS

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MICROFLUIDICS MARKET
• 3.2 MICROFLUIDICS MARKET, BY REGION
• 3.3 MICROFLUIDICS MARKET, BY COUNTRY AND END USER
• 3.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Integration of microfluidics with 3D printing
  • 4.2.2 E-HEALTH AND DIGITAL DIAGNOSTICS DRIVING MICROFLUIDICS ADOPTION
    • 4.2.2.1 Increasing prevalence of chronic diseases fueling POC testing
    • 4.2.2.2 Increasing focus on data precision and accuracy
  • 4.2.3 RESTRAINTS
    • 4.2.3.1 Regulatory and clinical validation barriers
    • 4.2.3.2 Material selection for microfluidic devices
  • 4.2.4 OPPORTUNITIES
    • 4.2.4.1 Advancing microfluidics for real-time food safety monitoring
    • 4.2.4.2 Rising demand for organ-on-a-chip platforms in precision medicine
  • 4.2.5 CHALLENGES
    • 4.2.5.1 Limited adoption of microfluidic devices
    • 4.2.5.2 Technical and operational limitations
• 4.3 UNMET NEEDS
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

5 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION

• 5.1 KEY TECHNOLOGIES
  • 5.1.1 MICROFABRICATION
  • 5.1.2 MATERIAL SCIENCE
  • 5.1.3 OPTOFLUIDICS
• 5.2 COMPLEMENTARY TECHNOLOGIES
  • 5.2.1 MICRO-ELECTRO-MECHANICAL SYSTEMS (MEMS)
  • 5.2.2 WEARABLE & IMPLANTABLE MICROFLUIDICS
• 5.3 PATENT ANALYSIS
  • 5.3.1 INNOVATIONS AND PATENT REGISTRATIONS
• 5.4 FUTURE APPLICATIONS
• 5.5 IMPACT OF AI/GENAI ON MICROFLUIDICS MARKET
  • 5.5.1 TOP USE CASES AND MARKET POTENTIAL
  • 5.5.2 BEST PRACTICES IN MICROFLUIDICS
  • 5.5.3 CASE STUDIES OF AI IMPLEMENTATION IN MICROFLUIDICS MARKET
  • 5.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 5.5.5 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN MICROFLUIDICS MARKET
• 5.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 NORTH AMERICA
    • 5.7.1.1 US
    • 5.7.1.2 Canada
  • 5.7.2 EUROPE
  • 5.7.3 ASIA PACIFIC
    • 5.7.3.1 Japan
    • 5.7.3.2 China
    • 5.7.3.3 India
  • 5.7.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 6.1 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 6.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.1.2 BUYING CRITERIA
• 6.2 DECISION-MAKING PROCESS
• 6.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 6.4 UNMET NEEDS FROM END USERS

7 INDUSTRY TRENDS

• 7.1 PORTER'S FIVE FORCES ANALYSIS
  • 7.1.1 THREAT OF NEW ENTRANTS
  • 7.1.2 THREAT OF SUBSTITUTES
  • 7.1.3 BARGAINING POWER OF SUPPLIERS
  • 7.1.4 BARGAINING POWER OF BUYERS
  • 7.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 7.2 MACROECONOMIC INDICATORS
  • 7.2.1 INTRODUCTION
  • 7.2.2 HEALTHCARE EXPENDITURE AND INFRASTRUCTURE OUTLOOK
  • 7.2.3 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 7.2.4 MACROECONOMIC OUTLOOK FOR EUROPE
  • 7.2.5 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 7.2.6 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 7.2.7 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 7.2.8 TRENDS IN GLOBAL MICROFLUIDICS INDUSTRY
• 7.3 VALUE CHAIN ANALYSIS
  • 7.3.1 RESEARCH & DEVELOPMENT
  • 7.3.2 RAW MATERIAL PROCUREMENT & MANUFACTURING
  • 7.3.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES
• 7.4 ECOSYSTEM ANALYSIS
• 7.5 PRICING ANALYSIS
  • 7.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 7.5.2 AVERAGE SELLING PRICE OF MICROFLUIDIC COMPONENTS, BY KEY PLAYERS
• 7.6 TRADE DATA ANALYSIS
  • 7.6.1 IMPORT DATA (HS CODE 3822)
  • 7.6.2 EXPORT DATA (HS CODE 3822)
• 7.7 KEY CONFERENCES & EVENTS, 2026-2027
• 7.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 7.9 INVESTMENT & FUNDING SCENARIO
• 7.10 CASE STUDY ANALYSIS
  • 7.10.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ
  • 7.10.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO
  • 7.10.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY
• 7.11 IMPACT OF 2025 US TARIFFS ON MICROFLUIDICS MARKET
  • 7.11.1 INTRODUCTION
  • 7.11.2 KEY TARIFF RATES
  • 7.11.3 PRICE IMPACT ANALYSIS
  • 7.11.4 IMPACT ON COUNTRY/REGION
  • 7.11.5 IMPACT ON END-USE INDUSTRIES

8 MICROFLUIDICS MARKET, BY PRODUCT

• 8.1 INTRODUCTION
• 8.2 MICROFLUIDICS-BASED DEVICES
  • 8.2.1 HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS TO DRIVE MARKET
  • 8.2.2 POLYMERASE CHAIN REACTION (PCR) SYSTEMS
  • 8.2.3 MICROFLUIDIC CAPILLARY ELECTROPHORESIS
  • 8.2.4 NEXT-GENERATION SEQUENCING (NGS) SYSTEMS
  • 8.2.5 DROPLET & PARTICLE PRODUCTION SYSTEMS
• 8.3 OTHER DEVICES
• 8.4 MICROFLUIDIC COMPONENTS
  • 8.4.1 CRUCIAL FOR CONTINUOUS HEALTH MONITORING
  • 8.4.2 MICROFLUIDIC COMPONENTS, BY TYPE
    • 8.4.2.1 Microfluidic chips
    • 8.4.2.2 Flow & pressure sensors
    • 8.4.2.3 Flow & pressure controllers
    • 8.4.2.4 Microfluidic valves
    • 8.4.2.5 Micropumps
    • 8.4.2.6 Microneedles
    • 8.4.2.7 Other microfluidic components
  • 8.4.3 MICROFLUIDIC COMPONENTS, BY MATERIAL
    • 8.4.3.1 Silicon
    • 8.4.3.2 Polymethyl methacrylate (PMMA)
    • 8.4.3.3 Polydimethylsiloxane (PDMS)
    • 8.4.3.4 Cyclic olefin copolymer (COC)
    • 8.4.3.5 Glass
    • 8.4.3.6 OTHER MATERIALS

9 MICROFLUIDICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 IN VITRO DIAGNOSTICS (IVD)
  • 9.2.1 CLINICAL DIAGNOSTICS
    • 9.2.1.1 Growing focus on early disease detection to drive market
  • 9.2.2 POINT-OF-CARE TESTING (POCT)
    • 9.2.2.1 Increasing demand for decentralized infectious disease testing to drive market
  • 9.2.3 VETERINARY DIAGNOSTICS
    • 9.2.3.1 Rising demand for rapid, field-deployable veterinary diagnostics to drive market
• 9.3 THERAPEUTICS
  • 9.3.1 DRUG DELIVERY
    • 9.3.1.1 Ability to enable scalable production of polymer-based drug particles to drive market
  • 9.3.2 WEARABLE
    • 9.3.2.1 Ability to enable proactive management of hydration, metabolic status, and disease biomarkers to drive market
• 9.4 PHARMACEUTICAL & LIFE SCIENCE RESEARCH
  • 9.4.1 LAB ANALYTICS
    • 9.4.1.1 Proteomic analysis
      • 9.4.1.1.1 Utilization of proteomes-on-a-chip devices for therapeutic development to drive market
    • 9.4.1.2 Genomic analysis
      • 9.4.1.2.1 High-throughput, cost-effective genomic analysis enabled by microfluidics
    • 9.4.1.3 Cell-based assays
      • 9.4.1.3.1 Microfluidic co-cultures enable precise, high-throughput modeling of complex tissues for drug testing and disease research
    • 9.4.1.4 Capillary electrophoresis
      • 9.4.1.4.1 Enables high-throughput, precise, and cost-efficient protein and nucleic acid analysis
  • 9.4.2 MICRODISPENSING
    • 9.4.2.1 Suitability for low-viscosity applications to support market growth
  • 9.4.3 MICROREACTORS
    • 9.4.3.1 Growing adoption of continuous flow synthesis in research & development to drive market

10 MICROFLUIDICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & DIAGNOSTIC CENTERS
  • 10.2.1 RISING DEPENDENCE ON RAPID MICROFLUIDIC MOLECULAR DIAGNOSTICS TO DRIVE GROWTH
• 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.3.1 STRONG ADOPTION OF MICROFLUIDIC TECHNOLOGIES FOR PRECISE FORMULATION, NANOPARTICLE PRODUCTION, AND TOXICITY TESTING TO DRIVE GROWTH
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO DRIVE GROWTH

11 MICROFLUIDICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 US
    • 11.2.1.1 Expansion of applications beyond traditional diagnostics to drive market
  • 11.2.2 CANADA
    • 11.2.2.1 Government funding and collaborative ecosystems to support growth
• 11.3 EUROPE
  • 11.3.1 GERMANY
    • 11.3.1.1 Ongoing investments in semiconductors and microelectronics to drive market
  • 11.3.2 FRANCE
    • 11.3.2.1 Rising demand for advanced lab-on-chip and organ-on-chip solutions to drive market
  • 11.3.3 UK
    • 11.3.3.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand
  • 11.3.4 ITALY
    • 11.3.4.1 Shift toward cost-efficient microfluidic platforms for diagnostics, environmental testing, and advanced biomedical research to drive market
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing demand for accessible point-of-care and lab-on-chip solutions to drive market
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
    • 11.4.1.1 Government support and strategic partnerships to drive market
  • 11.4.2 JAPAN
    • 11.4.2.1 Government support, innovation, and industry-academia collaboration to drive growth
  • 11.4.3 INDIA
    • 11.4.3.1 Growing biotech startup ecosystem and research from premier institutions to drive market
  • 11.4.4 AUSTRALIA
    • 11.4.4.1 Innovation ecosystem, R&D strength, and precision engineering to support growth
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Advanced research, global partnerships, and next-gen technologies to drive market
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 BRAZIL
    • 11.5.1.1 Rising investment in healthtech and emphasis on molecular diagnostics to drive market
  • 11.5.2 MEXICO
    • 11.5.2.1 Growing demand for advanced diagnostics and biotech innovation to drive market
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GCC COUNTRIES
    • 11.6.1.1 Disease burden and healthcare modernization to drive market
  • 11.6.2 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 12.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET
• 12.4 REVENUE ANALYSIS, 2022-2024
• 12.5 MARKET SHARE ANALYSIS, 2024
• 12.6 RANKING OF KEY MARKET PLAYERS
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product footprint
    • 12.7.5.4 Application footprint
    • 12.7.5.5 End user footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.8.5.1 List of key startup/SME players
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPANY VALUATION & FINANCIAL METRICS
  • 12.9.1 FINANCIAL METRICS
  • 12.9.2 COMPANY VALUATION
• 12.10 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 12.11 COMPETITIVE SCENARIO
  • 12.11.1 PRODUCT LAUNCHES & APPROVALS
  • 12.11.2 DEALS
  • 12.11.3 EXPANSIONS
  • 12.11.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ILLUMINA, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BIOMERIEUX
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches/approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 THERMO FISHER SCIENTIFIC INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches/approvals
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 ABBOTT LABORATORIES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Key strengths
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 PARKER HANNIFIN CORP
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 SMC CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches
  • 13.1.8 IDEX CORPORATION
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 FORTIVE
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 REVVITY, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 AGILENT TECHNOLOGIES, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product approvals/launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Expansions
  • 13.1.12 BIO-RAD LABORATORIES, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches
      • 13.1.12.3.2 Deals
  • 13.1.13 BECTON, DICKINSON AND COMPANY
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches/approvals
      • 13.1.13.3.2 Deals
      • 13.1.13.3.3 Expansions
  • 13.1.14 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches/approvals
      • 13.1.14.3.2 Deals
  • 13.1.15 STANDARD BIOTOOLS
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches/approvals
      • 13.1.15.3.2 Deals
  • 13.1.16 QUIDELORTHO CORPORATION
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product approvals
      • 13.1.16.3.2 Deals
      • 13.1.16.3.3 Expansions
  • 13.1.17 AIGNEP S.P.A.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Deals
  • 13.1.18 DOLOMITE MICROFLUIDICS
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product launches
      • 13.1.18.3.2 Deals
      • 13.1.18.3.3 Other developments
  • 13.1.19 ELVEFLOW
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 NANOSTRING TECHNOLOGIES
  • 13.2.2 INNOVATIVE BIOCHIPS, LLC
  • 13.2.3 FLUIDIC ANALYTICS
  • 13.2.4 HORIBA
  • 13.2.5 MICRONIT B.V.
  • 13.2.6 EMULATE, INC.
  • 13.2.7 SPHERE BIO
  • 13.2.8 ZEON CORPORATION
  • 13.2.9 QIAGEN N.V.

14 RESEARCH METHODOLOGY

• 14.1 RESEARCH DATA
• 14.2 RESEARCH DESIGN
  • 14.2.1 SECONDARY RESEARCH
    • 14.2.1.1 Objectives of secondary research
    • 14.2.1.2 Key data from secondary sources
  • 14.2.2 PRIMARY RESEARCH
    • 14.2.2.1 Objectives of primary research
    • 14.2.2.2 Key industry insights
• 14.3 MARKET SIZE ESTIMATION METHODOLOGY
  • 14.3.1 BOTTOM-UP APPROACH
    • 14.3.1.1 Approach 1: Company revenue estimation approach
    • 14.3.1.2 Approach 2: Customer-based market estimation
    • 14.3.1.3 Approach 3: Primary interviews
  • 14.3.2 TOP-DOWN APPROACH
• 14.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 14.5 MARKET SHARE ASSESSMENT
• 14.6 RESEARCH ASSUMPTIONS
• 14.7 RESEARCH LIMITATIONS
• 14.8 RISK ASSESSMENT

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS